Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketamine is a dissociative anesthetic used medically for the induction and maintenance of anesthesia in both humans and animals. It is also used off-label as a treatment for depression and as an analgesic. Ketamine acts primarily as an antagonist of the N-methyl-D-aspartate (NMDA) receptor on glutamate binding sites in the central nervous system. This NMDA receptor antagonism is responsible for its anesthetic effects (including sedation and amnesia), analgesia (pain relief), dissociation from environment and pain perception ("dissociative anesthesia"), psychotomimetic effects (hallucinations), and neuroprotection. The drug has additional mechanisms including enhancement of descending serotonergic pathways. Ketamine is available as a racemic mixture containing equal parts esketamine (S-ketamine) and arketamine (R-ketamine); esketamine has higher potency at the NMDA receptor. It can be administered intravenously or intramuscularly for medical use; it is also abused recreationally due to its hallucinogenic properties. Esketamine nasal spray has been developed specifically for treatment-resistant depression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketamine.